Protamine Zinc Recombinant Human Insulin

Verify with FDA CVM →

1,762 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,762
Total Reports
81
Deaths Reported
460.0%
Death Rate

Active Ingredients

Protamine Zinc Recombinant Human Insulin

Administration Routes

UnknownSubcutaneousParenteralOralIntramuscularSubconjunctival

Species Affected

Cat 783
Unknown 757
Dog 215
Human 7

Most Affected Breeds

Unknown 764
Domestic Shorthair 448
Cat (unknown) 157
Domestic Longhair 67
Domestic Mediumhair 29
Siamese 22
Dog (unknown) 18
Retriever - Labrador 18
Terrier - Yorkshire 16
Maine Coon 15

Most Reported Reactions

Containers, Damaged 388
INEFFECTIVE, GLYCEMIC CONTROL 377
Lack of efficacy - NOS 296
Vials, Damaged 231
Hypoglycaemia 165
Appearance, Abnormal 79
Vomiting 68
Product Defect, General 67
INEFFECTIVE, LOSS OF EFFECT 66
Death by euthanasia 60
Seal, Abnormal 47
Lethargy (see also Central nervous system depression in 'Neurological') 45

Outcome Breakdown

Outcome Unknown
707 (70.2%)
Recovered/Normal
172 (17.1%)
Euthanized
60 (6.0%)
Ongoing
47 (4.7%)
Died
21 (2.1%)

Data Summary

Metric Value
Total adverse event reports 1,762
Reports involving death 81
Case-fatality rate (reported events) 460.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Protamine Zinc Recombinant Human Insulin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,762 adverse event reports referencing Protamine Zinc Recombinant Human Insulin, including 81 reports in which the animal died — a 460.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Protamine Zinc Recombinant Human Insulin. Reported administration routes include Unknown, Subcutaneous, Parenteral, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Protamine Zinc Recombinant Human Insulin reports are Cat (783 reports), Unknown (757 reports), Dog (215 reports), with Cat accounting for the largest share. Within those species, Unknown (764), Domestic Shorthair (448), Cat (unknown) (157) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Protamine Zinc Recombinant Human Insulin are Containers, Damaged (388), INEFFECTIVE, GLYCEMIC CONTROL (377), Lack of efficacy - NOS (296), Vials, Damaged (231). Of the 1,007 reports with a coded outcome, Outcome Unknown is the leading category at 70.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Protamine Zinc Recombinant Human Insulin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial